Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

250
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
250
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

261
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
261
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

167
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
167
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

269
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
269
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

188
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
188

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological manifestations in children with SARS-CoV-2 infection: a French multicentric cohort.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2025
Same author

Clinical trial knowledge in families of children with epilepsy. A survey from a French Center for Rare Epilepsies.

Revue neurologique·2025
Same author

mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations.

Revue neurologique·2023
Same author

A simple novel approach for detecting blood-brain barrier permeability using GPCR internalization.

Neuropathology and applied neurobiology·2020
Same author

Lennox-Gastaut syndrome: New treatments and treatments under investigation.

Revue neurologique·2020
Same author

Pharmacological treatment of attention-deficit/hyperactivity disorder in children and adolescents with epilepsy.

Revue neurologique·2019

Related Experiment Video

Updated: May 13, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.9K

Targeted therapies in epilepsies.

S Auvin1

  • 1Pediatric Neurology Department, CRMR épilepsies rares, AP-HP, Robert-Debré University Hospital, Paris, France; Institut hospitalo-universitaire Robert-Debré du cerveau de l'enfant, Paris, France; Inserm NeuroDiderot, université Paris Cité, Paris, France; Institut universitaire de France (IUF), Paris, France.

Revue Neurologique
|April 12, 2025
PubMed
Summary
This summary is machine-generated.

Precision medicine shows promise for rare pediatric epilepsies, but translating preclinical findings into effective treatments remains a challenge. Further clinical validation is needed to confirm efficacy for drug-resistant epilepsy.

Keywords:
Antiepileptic drugsAntiseizure medicationDrug repositioningDrug resistanceEpilepsyPrecision medicine

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.4K
Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
09:46

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

Published on: March 8, 2015

10.9K

Related Experiment Videos

Last Updated: May 13, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.9K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.4K
Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
09:46

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

Published on: March 8, 2015

10.9K

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • Drug-resistant epilepsy remains a significant challenge despite advances in antiseizure medications.
  • Precision medicine offers targeted treatment strategies for rare pediatric epilepsies.
  • Historical examples like pyridoxine for antiquitin deficiency and ketogenic diet for GLUT1 deficiency syndrome illustrate precision approaches.

Purpose of the Study:

  • To explore the potential of precision medicine in treating rare pediatric epilepsies.
  • To assess the translation of preclinical findings into clinical efficacy for drug-resistant epilepsy.
  • To discuss the challenges and future directions in precision epilepsy treatment.

Main Methods:

  • Review of existing literature on precision medicine in epilepsy.
  • Analysis of preclinical evidence and clinical trial outcomes.
  • Case examples of successful and challenging precision treatments.

Main Results:

  • Preclinical research has identified numerous compounds for epilepsy treatment.
  • Clinical trials, such as everolimus for tuberous sclerosis complex, show promise.
  • Translational challenges exist, as seen with quinidine in KCNT1-related epilepsy, with heterogeneous outcomes.

Conclusions:

  • Precision medicine holds potential for mechanism-driven treatments in rare epilepsies.
  • Clinical trial validation is crucial for compounds identified at the preclinical level.
  • The overall efficacy and disease-modifying effects of these precision approaches in drug-resistant epilepsy require further investigation.